ArticleCureus2026
The Rising Inpatient Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From the Nationwide Inpatient Sample (2018-2022).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly common and is a growing public health concern. However, data on MASLD prevalence and outcomes among hospitalized adults in the United States are limited. Therefore, this study sought to evaluate the inpatient burden of MASLD, along with associated outcomes and patterns of resource utilization. Methods We analyzed 2018-2022 Nationwide Inpatient Sample (NIS) data for adult MASLD hospitalizations using the International Classification of Diseases, 10th Revision (ICD-10) codes and excluded secondary liver diseases. Survey-weighted multivariable models assessed the prevalence of the condition and the association between MASLD and inpatient mortality, adjusting for demographic, clinical, and hospital-level confounders. Sensitivity models included cirrhosis and hepatocellular carcinoma (HCC). Results Among 144 million adult hospitalizations, the prevalence of MASLD rose from 1.77% to 3.90% during the surveyed period. Crude MASLD mortality was lower in 2018-2021 but higher in 2022. Adjusted models showed year-to-year variation in the association with mortality. Including cirrhosis and HCC in the model showed that MASLD was associated with lower mortality, but the results depended on model adjustments. Older age, cardiovascular disease, chronic kidney disease, cancer, and cirrhosis were predictors of mortality among patients with MASLD. Conclusions The rate of MASLD among hospitalized adults in the United States rose from 2018 to 2022. Associations with mortality differed across years and depending on the analytic adjustments used. These findings at the discharge level should not be taken as evidence of either beneficial or harmful effects of MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.